# DESCRIPTION

## GOVERNMENT RIGHTS CLAUSE

- acknowledge government rights

## FIELD OF THE INVENTION

- define field of medicine

## BACKGROUND

- describe retinitis pigmentosa

## SUMMARY OF THE INVENTION

- outline CRISPR-based treatment method

## DETAILED DESCRIPTION OF THE INVENTION

- define key terms
- describe modulation and pharmaceutically acceptable carriers
- introduce retinitis pigmentosa and its challenges
- discuss current mutation-focused approaches and limitations
- introduce gene editing tools using CRISPR/Cas9
- describe the Inventors' hypothesis and approach using CRISPR/Cas9

### Genomic Editing.

- introduce genomic editing as a tool for correcting genetic mutations
- describe site-specific chromosomal integration using genome engineering
- motivate conventional technologies such as ZFNs and TALENs
- describe limitations of ZFNs and TALENs
- introduce CRISPR-Cas system as a flexible and powerful tool
- describe the mechanism of CRISPR-Cas system
- highlight advantages of CRISPR-Cas system over ZFNs and TALENs
- discuss potential clinical applications of CRISPR-Cas system
- describe proof-of-concept of prophylactic prevention and reversal of retinal defects using CRISPR
- outline a method of treatment using CRISPR-Cas system
- describe in vivo and in vitro methods of genomic editing using CRISPR-Cas system
- describe a composition including a vector encoding a CRISPR protein and one or more guide RNAs

### Animal Model

- introduce S334ter-line-3 rat model

### CRISPR/Cas9 Constructs, Generally

- motivate CRISPR/Cas9 for retinal degeneration

### CRISPR/Cas9 Constructs, Specifically

- design gRNA for rhodopsin gene knockout

### Methods

- design CRISPR/Cas9/guide-RNA constructs
- inject constructs into S334ter-3 rats
- evaluate photoreceptor preservation
- analyze DNA and protein
- determine Cas9 cleavage efficiency
- evaluate RhoS334 disruption in vivo
- motivate photoreceptor preservation following RhoS334 ablation
- motivate retinal synapse preservation following RhoS334 ablation
- quantify PR density and visual function in RhoS334 treated retinas
- describe dual AAV vectors
- describe Eosomes
- describe peptide for ocular delivery (POD)
- describe liposomes
- discuss results and implications

